GRI Bio, Inc. (GRI) vs 60 Degrees Pharmaceuticals, Inc. (SXTP)
Over the past 3 years, SXTP outperformed GRI — -79.23% vs -97.04% annualized total return (price plus dividends).
A side-by-side comparison of GRI Bio, Inc. and 60 Degrees Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
Total return — GRI vs SXTP
growth of $100 · dividends reinvested · last 3yMetrics side by side
Did SXTP beat GRI?
Over the past 3 years, SXTP outperformed GRI — -79.23% vs -97.04% annualized total return (price plus dividends).
Total return (annualized)
| Metric | GRI | SXTP |
|---|---|---|
| Total return (1Y) | -96.44% | -74.48% |
| Total return CAGR (3Y) | -97.04% | -79.23% |
| Total return CAGR (5Y) | -95.39% | N/A |
GRI is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).
Frequently asked
- Has SXTP beaten GRI?
- Over the past 3 years, SXTP outperformed GRI — -79.23% vs -97.04% annualized total return (price plus dividends).
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.